Federal officials review recommendations for R.S.V. Vaccine

Among Americans ages 60 to 74, only those with certain health conditions should receive the vaccines, the agency concluded.

In an unusual move, federal health officials have revised their recommendations on who should receive the respiratory syncytial virus vaccine.

The Centers for Disease Control and Prevention last year recommended that adults aged 60 or older can receive a single, lifetime dose of an R.S.V. vaccine. vaccine, in consultation with their health care providers.

On Wednesday, the agency's scientific advisors reframed this guideline. Based on recent safety and effectiveness data, they unanimously recommended that all Americans age 75 and older receive one dose of an R.S.V. vaccine. vaccine.

But for adults ages 60 to 74, the panel approved vaccination only for those with certain serious illnesses, such as heart disease or chronic pulmonary, advanced kidney disease. and diabetes with organ damage.

Councillors voted not to recommend the vaccine to other adults in this age group, although individuals can still consult their health care providers to assess the risk that infection poses to them. them.

Paradoxically, the new criteria could qualify more people to receive the vaccine, some advisers said. Not all people at high risk — some older Black Americans, for example — have access to a health care provider who can make this decision.

We are having difficulty retrieving article content.

Please enable JavaScript in your browser settings .

We are having difficulty retrieving article content.

Please enable JavaScript in your browser settings. browser.

We are having difficulty retrieving article content.

Please enable JavaScript in the browser settings. your browser.

We are having difficulty retrieving article content.

Please enable JavaScript in settings from your browser.

p>Thank you for your patience while we verify access. If you are in Reader mode, please exit and sign in to your Times account, or subscribe to the entire Times.

Thank you for your patience while we let's check access.

Already subscribed? Log in.

Want all the Times?